Explore the intersection of economics and public health in Burkina Faso with our deep dive into the cost-effectiveness of HPV vaccination—a critical tool in the fight against cervical cancer.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study.
Kiendrébéogo et al., BMC Health Serv Res 2023
DOI: 10.1186/s12913-023-10283-3
Oh, brace yourselves for a thrilling tale of economic evaluation, where the heroes are vaccines, and the villain is cervical cancer in Burkina Faso. In a world where cervical cancer rates are sky-high, the government, with a little help from their friends at Gavi, decided to vaccinate 9-year-old girls against HPV. But wait, there’s a twist! They didn’t just roll out the vaccines; they put on their accounting hats to see if it’s actually worth the bucks.
Enter the mighty static cohort model, a tool so powerful it can predict the impact of vaccines over a decade without moving an inch! The model, armed with data from GLOBOCAN 2020 and some local estimates, set out to determine the cost per DALY (that’s disability-adjusted life year, for the uninitiated) averted. They looked at four valiant vaccines: CERVARIX®, CECOLIN®, GARDASIL-4®, and GARDASIL-9®, each battling it out to be the most cost-effective champion against the no-vaccination dark ages.
And what did our model find? That HPV vaccination could be the knight in shining armor, potentially preventing up to 72% of cervical cancer cases and deaths. CECOLIN® emerged as the most budget-friendly option, costing less than a quarter of the national GDP per capita per DALY averted. But wait, there’s a plot twist! When cross-protection entered the scene, CECOLIN® still held the throne for cost-effectiveness, but CERVARIX® swooped in with more health benefits.
The annual cost of this life-saving quest? A mere US$ 2.9 million for CECOLIN® up to a whopping US$ 19.8 million for GARDASIL-9®. And for those who love a good bargain, a single dose strategy could slash costs and double the cost-effectiveness.
In the end, the moral of the story is clear: HPV vaccination is a cost-effective crusade in Burkina Faso. And with a little help from Gavi and some strategic vaccine choices, they could save even more lives and money. So, let’s give a round of applause for economic evaluations, the unsung heroes making sure we get the biggest bang for our buck in the battle against cervical cancer. Curtain falls.